Levofloxacin

Levaquin

Antibiotic • Fluoroquinolone

Premium

QT RiskNephrotoxic

Half-life

6-8 hours

Protein Binding

24-38%

Metabolized By

N/A

External

Drugs.com

Boxed warning

Tendinitis and tendon rupture
Peripheral neuropathy
CNS effects
Exacerbation of myasthenia gravis

Clinical alerts

Boxed warning

4 boxed warnings

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Mechanism of action

Inhibits bacterial DNA gyrase and topoisomerase IV

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Tuberculosis, Latent
·H Pylori Infection
·HELICOBACTER PYLORI INFECTIONS
·Granulomatous Mastitis
·Periprosthetic Joint Infection (PJI)

Monitoring

Therapeutic range: 2–8 mg/L; AUC/MIC ≥ 30-50

Interactions

No curated interaction pairs are recorded for Levofloxacin. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Nausea
Diarrhea
Headache
Insomnia
Dizziness

Food, alcohol & herbal

Food

Avoid taking with dairy or calcium supplements

Alcohol · moderate

May increase CNS side effects

Pharmacokinetics

Published parameters · PMID:15265146

Half-life: 6-8 hours
Protein binding: 24-38%
Clearance: 10 L/h; adult patients
Volume of distribution: 90 L
Bioavailability: 99%
Renally eliminated: 75%; Dose review in renal impairment
Model: 2-compartment

Pregnancy & lactation

Not recorded for Levofloxacin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement

Levofloxacin

Levaquin

Antibiotic • Fluoroquinolone

Premium

QT RiskNephrotoxic

Half-life

6-8 hours

Protein Binding

24-38%

Metabolized By

N/A

External

Drugs.com

Boxed warning

Tendinitis and tendon rupture
Peripheral neuropathy
CNS effects
Exacerbation of myasthenia gravis

Clinical alerts

Boxed warning

4 boxed warnings

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Mechanism of action

Inhibits bacterial DNA gyrase and topoisomerase IV

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Tuberculosis, Latent
·H Pylori Infection
·HELICOBACTER PYLORI INFECTIONS
·Granulomatous Mastitis
·Periprosthetic Joint Infection (PJI)

Monitoring

Therapeutic range: 2–8 mg/L; AUC/MIC ≥ 30-50

Interactions

No curated interaction pairs are recorded for Levofloxacin. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Nausea
Diarrhea
Headache
Insomnia
Dizziness

Food, alcohol & herbal

Food

Avoid taking with dairy or calcium supplements

Alcohol · moderate

May increase CNS side effects

Pharmacokinetics

Published parameters · PMID:15265146

Half-life: 6-8 hours
Protein binding: 24-38%
Clearance: 10 L/h; adult patients
Volume of distribution: 90 L
Bioavailability: 99%
Renally eliminated: 75%; Dose review in renal impairment
Model: 2-compartment

Pregnancy & lactation

Not recorded for Levofloxacin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement

Levofloxacin Drug Profile | PharmaGraphX